Zobrazit více v PubMed
CORSSMIT EP, ROMIJN JA. Clinical management of paragangliomas. Eur J Endocrinol 2014; 171 (6): R231–R243.
PubMed
SAVARGAONKAR P & WASSERMAN PG. Paragangliomas: classification, pathology, and differential diagnosis. Otolaryngologic clinics of North America 2001; 34(5): 845–62, v–vi.
PubMed
BOEDEKER CC. Paragangliomas and paraganglioma syndromes. Laryngorhinootologie 2011;90 suppl 1:S56–82. Doc03.
PubMed
SOBOL SM, DAILEY JC. Familial multiple cervical paragangliomas: report of a kindred and review of the literature. Otolaryngol Head Neck Surg 1990; 102(4):382–90
PubMed
SAJID MS, HAMILTON G, BAKER DM, JOINT VASCULAR RESEARCH GROUP. A multicenter review of carotid body tumour management. Eur J Vasc Endovasc Surg 2007; 34(2): 127–30.
PubMed
NAIK SM, SHENOY AM, NANJUNDAPPA, HALKUD R, CHAVAN P et al. Paragangliomas of the Carotid Body: Current Management Protocols and Review of Literature. Indian Journal of Surgical Oncology. 2013;4(3):305–312. doi:10.1007/s13193-013-0249-4.2013
PubMed
DOI
PMC
BOEDEKER C, HENSEN E, NEUMANN H, MALE W, VAN NEDERVEEN FH et al. Genetics of hereditary head and neck paragangliomas. Head Neck. 2014;36(6):907–916. 10.1002/hed.23436.
PubMed
DOI
JACKSON CG, GLASSCOCK ME, HARRIS PF. Glomus tumours: Diagnosis, classification and management of large lesions. Otolaryngol. 1982;08:401–406.
PubMed
FISCH U, MATTOX D. Microsurgery of the Skull Base. New York: Thieme; 1988
BILLER HF, LAWSON W, SOM P, ROSENFELD R. Glomus vagale tumors. Ann Otol Rhinol Laryngol 1989;98(1 Pt 1):21–26
PubMed
WATSON DJ. Nasal paraganglioma. J Laryngol Otol. 1988;102:526–9
PubMed
LANGERMAN A, ATHAVALE SM, RANGARAJAN SV, SINARD RJ, NETTERVILLE JM. Natural History of Cervical Paragangliomas: outcomes of Observation of 43 Patients1993–2010. Arch Otolaryngol Head Neck Surg. 2012;138(4):341–345. doi:10.1001/archoto.2012.37
PubMed
DOI
BARNES L Paraganglioma of the larynx. A critical review of the literature. ORL J Otorhinolaryngol Relat Spec. 1991;53(4):220–34
PubMed
VON DOBSCHUETZ E, LEIJON H, SCHALIN-JÄNTTI C, SCHIAVI F, et al. A registry-based study of thyroid paraganglioma: Histological and genetic characteristics. Endocrine-Related Cancer. 2015; 22(2): 191–204. DOI: 10.1530/ERC-14-0558
PubMed
DOI
RINALDO A, MYSSIOREK D, DEVANEY KO, FERLITO A. Which paragangliomas of the head and neck have a higher rate of malignancy? Oral Oncol. 2004;40:458–60.
PubMed
Martucci V, Pacak K. Pheochromocytoma and paraganglioma: Diagnosis, genetics, management, and treatment. Current Problems in Cancer. 2014;38(1):7–41. 10.1016/j.currproblcancer.2014.01.001
PubMed
DOI
PMC
Kirmani S, Young W. Hereditary Paraganglioma-Pheochromocytoma Syndromes. Ncbinlmnihgov. 2017.
Available at: http://www.ncbi.nlm.nih.gov/books/NBK1548.
Accessed December 19, 2017.
Piccini V, Rapizzi E, Bacca A, Di Trapani, Pulli R et al. Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients. Endocrine Related Cancer. 2012;19(2):149–155. 10.1530/erc-11-0369
PubMed
DOI
Neumann H, Erlic Z, Boedeker C, Rybicki L, Robledo M. et al. Clinical Predictors for Germline Mutations in Head and Neck Paraganglioma Patients: Cost Reduction Strategy in Genetic Diagnostic Process as Fall-Out. Cancer Research 2009; 69(8), 3650–3656. 10.1158/0008-5472.can-08-4057
PubMed
DOI
LATIF F, TORY K, GNARRA JR, YAO M, DUH FM, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260 (5112): 1317–20.
PubMed
ENG C The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschprung’s disease. N Engl J Med 1996;335:943–51
PubMed
WHITE R AND O’CONNELL P. Identification and characterization of the gene for neurofibromatosis type 1. Current Opinion in Genetics & Development 1991; 115–19. doi:10.1016/0959-437X(91)80034-J.
PubMed
DOI
NEUMANN HP, BAUSCH B, MCWHINNEY SR, BENDER BU, GIMM O et al. Germ line mutations in non syndromic pheochromocytoma. New England Journal of Medicine 2002; 3461459–1466. doi:10.1056/NEJMoa020152.
PubMed
DOI
Baysal B, Ferrell R, Willett-Brozick J, Lawrence E, Myssiorek D, et al. Mutations in SDHD, a Mitochondrial Complex II Gene, in Hereditary Paraganglioma. Science. 2000;287(5454):848–851. 10.1126/science.287.5454.848.
PubMed
DOI
Astuti D, Latif F, Dallol A, Dahia P, Douglas F et al. (2001). Gene Mutations in the Succinate Dehydrogenase Subunit SDHB Cause Susceptibility to Familial Pheochromocytoma and to Familial Paraganglioma. The American Journal Of Human Genetics 2001; 69(1), 49–54. 10.1086/321282
PubMed
DOI
PMC
Niemann S & Müller U Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nature Genetics 2000; 26(3), 268–270. 10.1038/81551
PubMed
DOI
Burnichon N, Brière J, Libé R, Vescovo L, Rivière J et al. SDHA is a tumor suppressor gene causing paraganglioma. Human Molecular Genetics 2010; 19(15), 3011–3020. 10.1093/hmg/ddq206
PubMed
DOI
PMC
Qin Y, Yao L, King EE, Buddavarapu K, Lenci RE et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet 2010; 42:229–233. 10.1038/ng.533
PubMed
DOI
PMC
Comino-Mendez I, Gracia-Aznarez FJ, Schiavi F, Landa I, Leandro-García LJ et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet. 2011; 43:663–667. 10.1038/ng.861
PubMed
DOI
Castro-Vega L, Letouzé E, Burnichon N, Buffet A, Disderot PH et al. Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nature Communications. 2015;6:6044 10.1038/ncomms7044
PubMed
DOI
PMC
Gimenez-Roqueplo A, Dahia P, Robledo M. An Update on the Genetics of Paraganglioma, Pheochromocytoma, and Associated Hereditary Syndromes. Hormone and Metabolic Research. 2012;44(05):328–333. 10.1055/s-0031-1301302.
PubMed
DOI
SCHLISIO S, KENCHAPPA RS, VREDEVELD LC, GEORGE RE, STEWART R et al. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev. 2008;22(7):884–93. 10.1101/gad.1648608
PubMed
DOI
PMC
Ladroue C, Carcenac R, Leporrier M, Gad S, Le Hello C, et al. PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl JMed. 2008; 359:2685–92. 10.1056/NEJMoa0806277
PubMed
DOI
GAAL J, BURNICHON N, KORPERSHOEK E, RONCELIN I, BERTHERAT J et al. Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2010;95:1274–1278.
PubMed
Zhuang Z, Yang C, Lorenzo F, Merino M, Fojo T et al. Somatic HIF2AGain-of-Function Mutations in Paraganglioma with Polycythemia. New England Journal of Medicine. 2012;367(10):922–930. 10.1056/nejmoa1205119
PubMed
DOI
PMC
OUDIJK L, DE KRIJGER RR, RAPA I, BEUSCHLEIN F, DE CUBAS AA et al. H-RAS Mutations Are Restricted to Sporadic Pheochromocytomas Lacking Specific Clinical or Pathological Features: Data From a Multi-Institutional Series. J Clin Endocrinol Metab. 2014; 99(7): E1376–E1380. 10.1210/jc.2013-3879
PubMed
DOI
de Cubas A, Leandro-Garcia L, Schiavi F, Mancikova V, Comino-Méndez I et al. Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways. Endocrine Related Cancer. 2013;20(4):477–493. 10.1530/erc-12-0183.
PubMed
DOI
Letouzé E, Martinelli C, Loriot C, Burnichon N, Abermil N et al. SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma. Cancer Cell. 2013;23(6):739–752. 10.1016/j.ccr.2013.04.018.
PubMed
DOI
de Cubas A, Korpershoek E, Inglada-Perez L, Letouzé E, Currás-Freixes M et al. DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers. Clinical Cancer Research. 2015;21(13):3020–3030. 10.1158/1078-0432.ccr-14-2804.
PubMed
DOI
Burnichon N, Buffet A, Gimenez-Roqueplo A. Pheochromocytoma and paraganglioma: molecular testing and personalized medicine. Current Opinion in Oncology. 2016;28(1):5–10. 10.1097/cco.0000000000000249
PubMed
DOI
Crona J, Delgado, Verdugo A, Maharjan R, Stalberg P, Granberg D et al. Somatic Mutations inH-RASin Sporadic Pheochromocytoma and Paraganglioma Identified by Exome Sequencing. The Journal of Clinical Endocrinology & Metabolism. 2013;98(7):E1266–E1271. 10.1210/jc.2012-4257
PubMed
DOI
EISENHOFER G, Huynh T, Pacak K, Brouwers F, Walther M et al. Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocrine Related Cancer. 2004;11(4):897–911. 10.1677/erc.1.00838
PubMed
DOI
Dahia P, Ross K, Wright M, Hayashida CY, Santagata S et al. A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas. PLoS Genetics. 2005;1(1):e8 10.1371/journal.pgen.0010008
PubMed
DOI
PMC
López-Jiménez E, Gómez-López G, Leandro-García L, Munoz I, Schiavi F et al. Research Resource: Transcriptional Profiling Reveals Different Pseudohypoxic Signatures in SDHB and VHL-Related Pheochromocytomas. Molecular Endocrinology. 2010;24(12):2382–2391. 10.1210/me.2010-0256
PubMed
DOI
PMC
Burnichon N, Vescovo L, Amar L, Libe R, de Reynies A et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Human Molecular Genetics. 2011;20(20):3974–3985. 10.1093/hmg/ddr324
PubMed
DOI
Bayley J, Kunst H, Cascon A, Sampietro ML, Gaal J et al. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. The Lancet Oncology. 2010;11(4):366–372. 10.1016/s1470-2045(10)70007-3
PubMed
DOI
FAVIER J, BRIÈRE JJ, BURNICHON N, RIVIÈRE J, VESCOVO L, et al. The Warburg Effect Is Genetically Determined in Inherited Pheochromocytomas. PLOS ONE 2009; 4(9): e7094.
PubMed
PMC
Pasini B, Stratakis C. SDH mutations in tumorigenesis and inherited endocrine tumors: lesson from the phaeochromocytoma-paraganglioma syndromes. Journal Of Internal Medicine 2009; 266(1), 19–42. 10.1111/j.1365-2796.2009.02111.x
PubMed
DOI
PMC
Burnichon N, Rohmer V, Amar L, Herman P, Leboulleux S. et al. The Succinate Dehydrogenase Genetic Testing in a Large Prospective Series of Patients with Paragangliomas. The Journal Of Clinical Endocrinology & Metabolism 2009; 94(8), 2817–2827. 10.1210/jc.2008-2504
PubMed
DOI
SCHIAVI F, DEMATTÈ S, CECCHINI ME, TASCHIN E, BOBISSE S, DEL PIANO A et al. The endemic paraganglioma syndrome type 1: Origin, spread, and clinical expression. Journal of Clinical Endocrinology and Metabolism. 2012; 97(4). 10.1210/jc.2011-2597
PubMed
DOI
Benn D, Gimenez-Roqueplo A, Reilly J, Bertherat J, Burgess J et al. Clinical Presentation and Penetrance of Pheochromocytoma/Paraganglioma Syndromes, The Journal of Clinical Endocrinology & Metabolism. 2006;91(3):827–836. 10.1210/jc.2005-1862.
PubMed
DOI
van Duinen N, Corssmit E, de Jong W, Brookman D, Kema I et al. Plasma levels of free metanephrines and 3-methoxytyramine indicate a higher number of biochemically active HNPGL than 24-h urinary excretion rates of catecholamines and metabolites. European Journal of Endocrinology. 2013;169(3):377–382. 10.1530/eje-13-0529.
PubMed
DOI
VAN SCHOTHORST EM, JANSEN JC, GROOTERS E, PRINS DE, WIERSINGA JJ et al. Founder effect at PGL1 in hereditary head and neck paraganglioma families from the Netherlands. American Journal of Human Genetics. 1998;63(2):468–473
PubMed
PMC
VAN DER MEY AG, MAASWINKEL-MOOY PD, CORNELISSE CJ, SCHMIDT PH, VAN DE KAMP JJ. Genomic imprinting in hereditary glomus tumours: evidence for new genetic theory. Lancet. 1989; 2(8675):1291–4;
PubMed
PIGNY P, VINCENT A, CARDOT BAUTERS C, BERTRAND M, DE MONTPREVILLE VT et al. Paraganglioma after maternal transmission of a succinate dehydrogenase gene mutation. J Clin Endocrinol Metab. 2008; 93(5):1609–15;
PubMed
Hensen E & Bayley J. Recent advances in the genetics of SDH-related paraganglioma and pheochromocytoma. Familial Cancer 2011; 10(2), 355–363. 10.1007/s10689-010-9402-1
PubMed
DOI
PMC
NEUMANN HP, PAWLU C, PECZKOWSKA M, BAUSCH B, MCWHINNEY SR, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004;292:943–51
PubMed
HENSEN EF, JANSEN JC, SIEMERS MD, OOSTERWIJK JC, VRIENDS AH et al. The Dutch founder mutation SDHD.D92Y shows a reduced penetrance for the development of paragangliomas in a large multigenerational family. Eur J Hum Genet. 2009;18(1):62–6.
PubMed
PMC
VAN HULSTEIJN LT, DEKKERS OM, HES FJ, SMIT JW, CORSSMIT EP. Risk of malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers: a systematic review and meta-analysis. Journal of Medical Genetics 2012;49:768–776
PubMed
Vicha A, Musil Z, & Pacak K, Genetics of pheochromocytoma and paraganglioma syndromes. Current Opinion In Endocrinology & Diabetes And Obesity 2013; 20(3), 186–191. 10.1097/med.0b013e32835fcc45
PubMed
DOI
PMC
Niemann S, Muller U, Engelhardt D & Lohse P. Autosomal dominant malignant and catecholamine-producing paraganglioma caused by a splice donor site mutation in SDHC. Hum Genet 2003; 113(1), 92–4. 10.1158/1078-0432.CCR-10-0420
PubMed
DOI
Baysal B, Willett Brozick J, Filho P, Lawrence E, Myers E et al. An Alu-Mediated partial SDHC deletion causes familial and sporadic paraganglioma. Journal Of Medical Genetics 2004; 41(9), 703–709. 10.1136/jmg.2004.019224
PubMed
DOI
PMC
Schiavi F, Boedeker C, Bausch B, Peçzkowska M, Gomez C. et al. Predictors and Prevalence of Paraganglioma Syndrome Associated With Mutations of the SDHC Gene. JAMA 2005; 294(16), 2057–63. 10.1001/jama.294.16.2057
PubMed
DOI
Neumann H, EnG C. The Approach to the Patient with Paraganglioma. The Journal Of Clinical Endocrinology & Metabolism 2009; 94(8), 2677–2683. 10.1210/jc.2009-0496
PubMed
DOI
PMC
PROYE C, VIX M, GOROPOULOS A, KERLO P, LECOMTE-HOUCKE M. High incidence of malignant pheochromocytoma in a surgical unit: 26 cases out of 100 patients operated from 1971 to 1991. J Endocrinol Invest. 1992;15:651–63.
PubMed
Ricketts C, Forman J, Rattenberry E, Bradshaw N, Lalloo F et al. Tutor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Human Mutation 2010; 31(1), 41–51. 10.1002/humu.21136
PubMed
DOI
KLEIN RD, JIN L, RUMILLA K, YOUNG WF, LLOYD RV. Germline SDHB mutations are common in patients with apparently sporadic sympathetic paragangliomas. Diagn Mol Pathol. 2008;17: 94–100.
PubMed
AMAR L, BAUDIN E, BURNICHON N, PEYRARD S, SILVERA S et al. Succinate dehydrogenase B gene mutations predict survival in subjects with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 2007;92:3822–28
PubMed
GIMENEZ-ROQUEPLO A, FAVIER J, RUSTIN P, RIEUBLAND C, CRESPIN M et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer research 2003; 63 (17): 5615–21.
PubMed
Hao H, Khalimonchuk O, Schraders M, Dephoure N, Bayley J. et al. SDH5, a Gene Required for Flavination of Succinate Dehydrogenase, Is Mutated in Paraganglioma. Science 2009; 325(5944), 1139–1142. 10.1126/science.1175689
PubMed
DOI
PMC
VAN BAARS F, VAN DEN BROEK P, CREMERS C, & VELDMAN J. FAMILIAL NON-CHROMAFFINIC PARAGANGLIOMAS (GLOMUS S). The Laryngoscope 1981; 91(6), 988–996. 10.1288/00005537-198106000-00019
PubMed
DOI
Kunst H, Rutten M, de Monnink J, Hoefsloot L, Timmers H. et al. SDHAF2 (PGL2-SDH5) and Hereditary Head and Neck Paraganglioma. Clinical Cancer Research 2011; 17(2), 247–254. 10.1158/1078-0432.ccr-10-0420\
PubMed
DOI
OFFERGELD C, Brase C, Yaremchuk S, MADER I, Rischke H et al. Head and neck paragangliomas: clinical and molecular genetic classification. Clinics (Sao Paulo) 2012; 67(SUPPL 1), 19–28. 10.6061/clinics/2012(Sup01)05
PubMed
DOI
PMC
Karasek D, Shah U, Frysak Z, Stratakis C, & Pacak K. An update on the genetics of pheochromocytoma. Journal Of Human Hypertension 2012; 27(3), 141–147. 10.1038/jhh.2012.20
PubMed
DOI
PMC
Boedeker C, Erlic Z, Richard S, Kontny U, Gimenez-Roqueplo A. et al. Head and Neck Paragangliomas in Von Hippel-Lindau Disease and Multiple Endocrine Neoplasia Type 2. The Journal Of Clinical Endocrinology & Metabolism 2009;, 94(6), 1938–1944. 10.1210/jc.2009-0354
PubMed
DOI
PMC
Pacak K, Jochmanova I, Prodanov T, Yang C, Merino MJ et al. New Syndrome of Paraganglioma and Somatostatinoma Associated With Polycythemia. J Clin Oncol. 2013. May 1; 31(13): 1690–1698. 10.1200/JCO.2012.47.1912
PubMed
DOI
PMC
Lorenzo FR, Yang C, Ng Tang Fui M, Vankayalapati H, Zhuang Z et al. A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med (Berl). 2013. April; 91(4):507–12. 10.1007/s00109-012-0967
PubMed
DOI
PMC
Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science. 1990; 249:181–186.
PubMed
Burnichon N, Buffet A, Parfait B, Letouze E, Laurendeau I et al. Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Hum Mol Genet. 2012; 21:5397–5405. 10.1093/hmg/dds374
PubMed
DOI
DeAngelis LM, Kelleher MB, Post KD, Fetell MR. Multiple paragangliomas in neurofibromatosis: a new neuroendocrine neoplasia. Neurology 1987;37:129–133.
PubMed
Bausch B, Borozdin W, Neumann HP; European-American Pheochromocytoma Study Group. Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma.N Engl J Med. 2006. June 22;354(25):2729–31. 10.1056/NEJMc066006
PubMed
DOI
Abermil N, Guillaud-Bataille M, Burnichon N, Venisse A, Manivet P et al. TMEM127 screening in a large cohort of patients with pheochromocytoma and/or paraganglioma. J Clin Endocrinol Metab. 2012; 97:E805–E809. 10.1210/jc.2011-3360
PubMed
DOI
Burnichon N, Cascon A, Schiavi F, Morales NP, Comino-Mendez I et al. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res. 2012; 18:2828–2837. 10.1158/1078-0432.CCR-12-0160
PubMed
DOI
Ivan HT, Haberberger T, Gervasi DC, Michelson KS, Gunzler V et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99:13459–64. 10.1073/pnas.192342099
PubMed
DOI
PMC
Adari H, Lowy DR, Willumsen BM, Der CJ, McCornick F. Guanosine triphosphatase activatingprotein (GAP) interacts with the p21 ras effector binding domain. Science. 1988;240:518–21. 10.1126/science.2833817
PubMed
DOI
King KS AND Pacak K. In Familial Pheochromocytomas and Paragangliomas. Mol Cell Endocrinol. 2014;386(0): 92–100. 10.1016/j.mce.2013.07.032.
PubMed
DOI
PMC
Sridhara SK, Yener M, Hanna E, Rich T, Jimenez C et al. Genetic Testing in Head and Neck Paraganglioma: Who, What, and Why? J Neurol Surg B 2013;74:236–240. 10.1055/s-0033-1342924
PubMed
DOI
PMC
Fakhry N, Niccoli-Sire P, Barlier-Seti A, Giorgi R, Giovanni A et al. Cervical paragangliomas: is SDH genetic analysis systematically required? Eur Arch Otorhinolaryngol 2008;265(5):557–563. 10.1007/s00405-007-0517-4
PubMed
DOI
Zhu WD, Wang ZY, Chai YC, Wang XW, Chen DY et al. Germline mutations and genotype-phenotype associations in head and neck paraganglioma patients with negative family history in China. Eur J Med Genet 2015; 58:433–438. 10.1016/j.ejmg.2015.05.008
PubMed
DOI
Heesterman BL, Bayley JP, Tops CM, Hes FJ, van Brussel BT et al. High prevalence of occult paragangliomas in asymptomatic carriers of SDHD and SDHB gene mutations. Eur J Hum Genet 2013; 21:469–470. 10.1038/ejhg.2012.203
PubMed
DOI
PMC
Welander J, Larsso C, Backdahl M, Hareni N, Sivler T et al. Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas. Hum Mol Genet. 2012;21:5406–5416.
PubMed
Chen H, Zhu W, Li X, Xue L, Wang Z et al. Genetic and epigenetic patterns in patients with the head- and-neck paragangliomas associate with differential clinical characteristics. J Cancer Res Clin Oncol 2017; 143:953–960. 10.1007/s00432-017-2355-0
PubMed
DOI
ZHIKRIVETSKAYA SO, SNEZHKINA AV, ZARETSKY AR, ALEKSEEV BY, POKROVSKY AV et al. Molecular markers of paragangliomas/pheochromocytomas. Oncotarget. 2017; 8(15):25756–25782.
PubMed
PMC